Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease.
Soran PeshbaharElizabeth BendstrupPublished in: European clinical respiratory journal (2020)
Polymyositis (PM) and dermatomyositis (DM) are subtypes of autoimmune inflammatory myopathies. Interstitial lung disease (ILD) involvement is common in PM/DM. There is no evidence base for immunosuppression in DM/PM-ILD and current evidence is based on case stories and expert opinions. We present a 63-year-old male with severe respiratory failure due to PM-ILD who was treated successfully with intravenous immunoglobulin, recovered the acute phase and survived more than 4 years.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- respiratory failure
- particulate matter
- air pollution
- rheumatoid arthritis
- polycyclic aromatic hydrocarbons
- idiopathic pulmonary fibrosis
- heavy metals
- extracorporeal membrane oxygenation
- water soluble
- high dose
- mechanical ventilation
- drug induced
- liver failure
- case report
- oxidative stress
- acute respiratory distress syndrome
- metabolic syndrome
- skeletal muscle
- risk assessment
- hepatitis b virus
- intensive care unit
- low dose
- disease activity
- weight loss